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Abstract: Diabetes is one of the most important comorbidities linked to the severity of all three known
human pathogenic coronavirus infections, including severe acute respiratory syndrome coronavirus 2.
Patients with diabetes have an increased risk of severe complications including Adult Respiratory Distress
Syndrome and multi-organ failure. Depending on the global region, 20–50% of patients in the coronavirus
disease 2019 (COVID-19) pandemic had diabetes. Given the importance of the link between COVID-19
and diabetes, we have formed an international panel of experts in the field of diabetes and endocrinology
to provide some guidance and practical recommendations for the management of diabetes during the
pandemic. We aim to briefly provide insight into potential mechanistic links between the novel coronavirus
infection and diabetes, present practical management recommendations, and elaborate on the differential
needs of several patient groups.
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COVID-19 targets 
human adrenal glands
COVID-19 develops due to infection 
with SARS-CoV-2, which particularly 
in elderly with certain comorbidities 
(eg, metabolic syndrome)1 can 
cause severe pneumonia and acute 
respiratory distress syndrome. Some 
patients with severe COVID-19 will 
develop a life-threatening sepsis with 
its typical manifestations including 
disseminated intravascular coagulation 
and multiorgan dysfunction.2 Latest 
evidence suggests that even early 
treatment with inhaled steroids 
such as budesonide might prevent 
clinical deterioration in patients with 
COVID-19.3 This evidence underlines the 
potentially important role for adrenal 
steroids in coping with COVID-19. 
The adrenal gland is an effector 
organ of the hypothalamic–pituitary–
adrenal axis and the main source of 
glucocorticoids, which are critical 
to manage and to survive sepsis. 
Therefore, patients with pre-existing 
adrenal insufficiency are advised to 
double their doses of glucocorticoid 
supplementation after developing 
moderate to more severe forms of 
COVID-19.4 
Adrenal glands are vulnerable to 
sepsis-induced organ damage and 
their high vascularisation and blood 
supply makes them particularly 
susceptible to endothelial dysfunction 
and haemorrhage. Accordingly, 
adrenal endothelial damage, bilateral 
haemorrhages, and infarctions have 
been already reported in patients 
with COVID-19.5 Adrenal glands 
contain the highest concentration 
of antioxidants to compensate 
enhanced generation of reactive 
oxygen species, side products of 
steroidogenesis, which together with 
elevated intra-adrenal inflammation 
can contribute to adrenocortical cell 
death.6 Furthermore, sepsis-associated 
critical illness-related corticosteroid 
insufficiency, which describes 
coexistence of the hypothalamic–
pituitary–adrenal  dysfunction, 
reduced cortisol metabolism, and 
tissue resistance to glucocorticoids, 
was reported in critically ill patients 
with COVID-19.7 Low cortisol and 
adrenocort icotropic  hormone 
(ACTH) responses during acute 
phase of infections consistent with 
critical illness-related corticosteroid 
insufficiency diagnosis (random 
plasma cortisol level lower than 
10 µg/dL) were reported in one study 
with patients suffering from mild to 
moderate COVID-19 manifestations.8 
It is however possible those other 
factors triggered by COVID-19 such 
as hypothalamic or pituitary damage, 
adrenal infarcts, or previously 
undiagnosed conditions, such as 
antiphospholipid syndrome, might 
be responsible for reduced function of 
adrenal glands. However, contrary to 
this observation, a study with patients 
with moderate to severe COVID-19 
revealed a very high cortisol response 
with values exceeding 744 nmol/L, 
which were positively correlated with 
severity of disease.9 In this clinical 
study,9 highly elevated cortisol 
concentrations showed an adequate 
adrenal cortisol production possibly 
reflecting the elevated stress level 
of those severely affected patients.9 
However, since ACTH measurements 
were not done, it is impossible to 
verify whether high concentrations 
of cortisol in those patients resulted 
from an increment of cortisol, or were 
confounded by reduced glucocorticoid 
metabolism.9
A critical and yet unsolved major 
question is whether SARS-CoV-2 
infection can contribute either 
directly or indirectly to adrenal gland 
dysfunction observed in some patients 
with COVID-19 or contribute to the 
slow recovery of some patients with 
long COVID.
We performed a comprehensive 
histopathological  examination 
of adrenal tissue sections from 
autopsies of patients that died due to 
COVID-19 (40 cases), collected from 
three different pathology centres 
in Regensburg, Dresden, and Zurich 
(appendix pp 1–3). We observed 
evidence of cellular damage and 
frequently small vessel vasculitis 
(endotheliitis) in the periadrenal fat 
tissue (six cases with low and 13 cases 
with high density; appendix p 10) and 
much milder occurrence in adrenal 
parenchyma (ten cases with low 
and one case with moderate score; 
appendix p 10), but no evidence 
of thrombi formation was found 
(appendix p 10). Endotheliitis has 
been scored according to a semi-
quantitative immunohistochemistry 
analysis as described in the appendix 
(p 4). Additionally, in the majority of 
cases (38 cases), we noticed enhanced 
perivascular lymphoplasmacellular 
infiltration of different density and 
sporadically a mild extravasation 
of erythrocytes (appendix p 10). 
However, no evidence of widespread 
haemorrhages and degradation 
of adrenocortical cells were found, 
which is consistent with histological 
findings reported previously.5 In 
another autopsy study analysing 
adrenal glands of patients with 
COVID-19, additional signs of acute 
fibrinoid necrosis of small vessels in 
adrenal parenchyma, subendothelial 
vacuolisation and apoptotic debris 
were found.5
Adrenal gland is frequently targeted 
by bacteria and viruses, including 
SARS-CoV,10 which was responsible 
for the 2002–04 outbreak of SARS in 
Asia. Considering that SARS-CoV-2 
shares cellular receptors with SARS-
CoV, including angiotensin-converting 
enzyme 2 and transmembrane 
protease serine subtype 2, its tropism 
to the adrenal gland is therefore 
conceivable. 
To investigate whether adrenal 
vascular cells and possibly steroid-
producing cells are direct targets of 
SARS-CoV-2, we examined SARS-
CoV-2 presence in adrenal gland tissues 
obtained from the 40 patients with 
COVID-19 (appendix pp 1–3). Adrenal 
tissues from patients who died before 
the COVID-19 pandemic were used as 
negative controls to validate antibody 
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The necrotic process is characterised 
by loss of membrane integrity and 
release of danger-associated molecular 
patterns, which further promote tissue 
inflammation (necroinflammation) 
involving enhanced activation of 
the complement system and related 
activation of neutrophils. Whether 
necroptosis might be involved in 
COVID-19-associated adrenal damage 
is currently unknown. In our study, 
we showed prominent expression 
of phospho Mixed Lineage Kinase 
Domain Like Pseudokinase (pMLKL) 
indicating necroptosis activation 
in adrenomedullary cells (appendix 
p 14) in adrenal glands of COVID-19 
patients. However, since we have 
also observed pMLKL expression 
in adrenal glands obtained from 
autopsies done before the COVID-19 
pandemic (controls), necroptosis 
activation in medullary cells might 
be a rather frequent and SARS-CoV-2 
independent event. However, contrary 
to the adrenal medulla, pMLKL 
positivity in the adrenal cortex was 
only found in virus-positive regions 
(appendix p 14). This finding suggests 
that SARS-CoV-2 infection might 
have directly triggered activation 
of necroptosis in infected cells in 
the adrenal cortex, whereas pMLKL 
expression in the adrenal medulla 
seems rather an indirect consequence 
of systemic inflammation. 
In summary, in our study of 
40 patients who died from COVID-19, 
we did not observe widespread 
degradation of human adrenals 
that might lead to manifestation 
of the adrenal crisis. However, our 
study shows that the adrenal gland 
is a prominent target for the viral 
infection and ensuing cellular damage, 
which could trigger a predisposition 
for adrenal dysfunction. Whether 
those changes directly contribute to 
adrenal insufficiency seen in some 
patients with COVID-19 or lead to its 
complications (such as long COVID) 
remains unclear. Large multicentre 
clinical studies should address this 
question.
RT-qPCR techniques for SARS-CoV-2 
positivity was only 23%, which is 
a technical limitation of our study 
possibly reflecting the low number of 
virus-positive cells. However, when 
considering triple-negative samples, 
an overall 53% consensus was found 
(appendix pp 7–8). 
Finally, to confirm the identity of 
infected cells, we have performed 
an ultrastructural analysis of adrenal 
tissue from a triple-positive patient 
case (by immunohistochemistry, ISH, 
and RT-qPCR), and found numerous 
SARS-CoV-2 virus-like particles in 
cells enriched with liposomes, which 
are typical markers of adrenocortical 
cells (figure C). The cortical identity of 
SARS-CoV-2 spike positive cells was 
also shown using serial tissue sections, 
demarcating regions with double 
positivity for viral protein and StAR 
RNA (appendix p 12). Furthermore, 
susceptibility of adrenocortical 
cells to SARS-CoV-2 infection was 
confirmed by in-vitro experiments 
(appendix p 7) showing detection of 
viral spike protein in adrenocortical 
carcinoma cells (NCI-H295R) cultured 
in a medium containing SARS-CoV-2 
(figure D), and its absence in mock-
treated control cells (figure E). We 
showed an uptake of viral particles 
in the adrenocortical cells, by ISH, 
immunohistochemistry, RT-qPCR 
and electron microscopy (figure A–C). 
Mechanistically, an uptake of SARS-
CoV-2 like particles might involve 
expression of ACE2 in vascular cells 
(appendix p 13) and perhaps of the 
shorter isoform of ACE2 together 
with TMPRSS2 and other known 
or currently unknown virus-entry 
facilitating factors in adrenocortical 
cells (appendix p 13). An example 
of such factor is scavenger receptor 
type 1, which is highly expressed in 
adrenocortical cells.11
Several forms of regulated cell 
necrosis were implicated in sepsis-
mediated adrenal gland damage.6 One 
of the prime examples of regulated 
necrosis triggered by sepsis-associated 
tissue inflammation is necroptosis. 
specificity. Using a monoclonal 
antibody (clone 1A9; appendix p 11), 
we detected SARS-CoV-2 spike protein 
in adrenocortical cells in 18 (45%) 
of 40 adrenal gland tissues (figure B; 
appendix p 12). In the same number 
of adrenal tissues (18 [45%] of 40), 
we have detected SARS-CoV-2 mRNA 
using in situ hybridisation (ISH; figure A; 
appendix p 12). The concordance rate 
between immunohistochemistry 
and ISH methods was 90% (36/40). 
Scattered and rather focal expression 
pattern of SARS-CoV-2 spike protein 
was found in the adrenal cortex 
(figure A and B; appendix p 12). In 
addition, SARS-CoV-2 expression was 
confirmed in 15 out of 30 adrenal gland 
tissues of patients with COVID-19 
by multiplex RT-qPCR (appendix 
pp 6–7). The concordance between 
ISH, immunohistochemistry, and 
Figure: Detection of SARS-CoV-2 in human adrenal gland from a patient who died 
due to COVID-19
(A) Detection of SARS-CoV-2 RNA by in situ hybridization (ISH; brown DAB staining) 
and (B) its spike protein by immunohistochemistry (red AEC staining) was found in 
the same region of two serial 1 μm-thick tissue sections of the adrenal gland. Inserts 
depict the same regions but were captured at lower magnification showing the chosen 
area of virus positivity (white squares). Scattered expression of either mRNA or 
protein can be found in the inner parts of the adrenal gland cortex close to the 
medulla. Scale bars in pictures from panel A and B represent 100 μm (10 μm in the 
insert image). (C) Ultrastructural examination of a SARS-CoV-2 triple positive 
(ISH, immunohistochemistry, and RT-qPCR) adrenal tissue showing numerous viral-
like particles in liposome (LIP)-rich adrenocortical cells. A scale bar represents 200 nm. 
A low magnification picture shown in the insert depicts the region of interest 
indicated by a green arrow in the enlarged picture. Scale bar in insert indicates 1 μm 
distance. (D) A positive immunofluorescent red signal (CY3) indicating the expression 
of spike protein in SARS-CoV-2 infected human adrenocortical cells. (E) Lack of 
positive signal (CY3) in mock-infected control cells. Adrenocortical cells were 
additionally stained with an antibody against side-chain cleavage enzyme (CYP11A1), 
which is a steroidogenic marker (green signal; CY5). Nuclei were counterstained with 
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